VEGFC–Macrophage Axis in NASH: Inhibition, Fibrosis, and SAR131675

Study Background and Research Question

Non-alcoholic steatohepatitis (NASH), a progressive subtype of non-alcoholic fatty liver disease (NAFLD), is marked by hepatic steatosis, inflammation, and fibrosis, and is a major cause of cirrhosis and liver-related mortality worldwide (reference paper). Recent studies implicate the vascular endothelial growth factor C (VEGFC)–VEGFR-3 signaling axis not only in lymphangiogenesis but also in modulating immune cell crosstalk within the liver's fibrogenic microenvironment. However, the precise role of hepatocyte-derived VEGFC in orchestrating macrophage behavior and fibrosis, and its suitability as a pharmacological target, remained poorly defined. The present study sought to elucidate whether downregulation or inhibition of VEGFC could disrupt the hepatocyte–macrophage axis, thereby attenuating NASH-associated hepatic fibrosis. The research further explored the comparative effects of the polyphenol naringin (NAR), genetic deletion of hepatocyte Vegfc, and pharmacological blockade using the selective VEGFR-3 inhibitor SAR131675, with a focus on macrophage phenotypic plasticity and fibrogenesis.

Key Innovation from the Reference Study

The core innovation of this work lies in defining VEGFC as a central regulator of hepatocyte-driven macrophage recruitment and phenotype switching in NASH. The study demonstrates that both naringin and SAR131675, an anti-lymphangiogenic agent, ameliorate hepatic fibrosis by suppressing VEGFC expression or signaling, thereby disrupting pathological macrophage infiltration and promoting a reparative Ly6Chigh-to-Ly6Clow transition (reference paper). The integration of clinical, animal, and in vitro data offers a comprehensive mechanistic link between VEGFC signaling and the fibrotic cascade.

Methods and Experimental Design Insights

To interrogate the VEGFC–macrophage axis, the authors employed a multifaceted approach:

• In vivo: A murine model of NASH fibrosis was established using 24 weeks of high-fat diet (HFD) feeding. Mice received either low- or high-dose naringin (NAR-L: 25 mg/kg/day, NAR-H: 50 mg/kg/day) or SAR131675 (30 mg/kg/day, administered for 16 weeks starting at week 9) (reference paper).
• Clinical correlation: Serum VEGFC levels were assayed in a hospital cohort (n=165), and hepatic VEGFC mRNA expression was examined using publicly available human datasets (GEO: GSE162694, GSE130970).
• Genetic model: Hepatocyte-specific Vegfc knockout mice (VegfcHep-cKO) were generated via conditional recombination (Vegfc^flox/flox crossed with Alb-CreERT2).
• In vitro: AML12 murine hepatocytes were subjected to oleic acid, recombinant VEGFC, or Vegfc knockdown/overexpression. Conditioned medium from these hepatocytes was used to stimulate bone marrow-derived macrophages (BMDMs), assessing migration and phenotypic markers.

Protocol Parameters

• in vivo SAR131675 dosing | 30 mg/kg/day, oral gavage | murine NASH fibrosis model | Dose based on prior potency and selectivity data to inhibit VEGFR-3 | product_spec
• Naringin dosing | 25–50 mg/kg/day, oral | murine NASH fibrosis model | Based on prior anti-fibrotic and safety data | reference paper
• VEGFC ELISA | serum, ng/mL | human clinical cohort | Standard diagnostic quantification | reference paper
• Hepatocyte-specific Vegfc KO | Vegfc^flox/flox × Alb-CreERT2 | murine mechanistic study | Dissects hepatocyte contribution to VEGFC axis | reference paper
• Macrophage migration assay | BMDM co-culture, % migrated | in vitro crosstalk | Measures VEGFC–VEGFR-3 effect on macrophage chemotaxis | reference paper
• VEGFC recombinant protein | 10–100 ng/mL | in vitro stimulation | Standard for pathway activation | workflow_recommendation

Core Findings and Why They Matter

Key outcomes from the study include:

• VEGFC upregulation in NASH: Both clinical and murine data revealed significant elevation of circulating and hepatic VEGFC in NAFLD/NASH compared to healthy controls (reference paper).
• Naringin and SAR131675 attenuate fibrosis: Treatment with NAR or the VEGFR-3 inhibitor SAR131675 reduced liver inflammation (ALT, AST), collagen deposition, and histological fibrosis scores. Both agents downregulated VEGFC and CCL2/CCR2 signaling, leading to decreased Ly6Chigh monocyte infiltration and a shift toward Ly6Clow reparative macrophages.
• Genetic validation: Hepatocyte-specific Vegfc knockout recapitulated the protective effects seen with pharmacological inhibition, confirming the key role of hepatocyte-derived VEGFC in driving macrophage-mediated fibrogenesis.
• In vitro mechanistic insight: Hepatocyte-derived VEGFC promoted BMDM migration via VEGFR-3 and sustained a pro-inflammatory Ly6Chigh phenotype by modulating IL-10 and CX3CR1. Both NAR and SAR131675 blocked these effects, disrupting the fibrogenic loop.

These findings directly implicate the VEGFC–VEGFR-3 axis as a modifiable driver of hepatic fibrosis, positioning selective VEGFR-3 inhibition as a mechanistically justified approach for anti-fibrotic intervention (reference paper).

Comparison with Existing Internal Articles

Recent internal reviews underscore the translational value of SAR131675 as a highly selective ATP-competitive VEGFR-3 inhibitor, with nanomolar potency and minimal off-target activity (internal article). Previous work has primarily highlighted its anti-lymphangiogenic and anti-angiogenic properties in oncology and lymphatic models, as well as its ability to inhibit lymphatic endothelial cell survival and migration (internal article). The current reference paper extends these findings into the context of metabolic liver disease, providing robust evidence that SAR131675 can also attenuate fibrogenesis by interfering with immune–vascular crosstalk. This expands the experimental utility of SAR131675 from cancer and lymphangiogenesis research to fibrosis and immunometabolic disease models. Compared to other inhibitors, SAR131675’s selectivity for VEGFR-3 (IC50: 23 nM) and lack of significant off-target kinase/receptor activity offer an advantage for dissecting pathway-specific roles (product_spec).

Limitations and Transferability

While these results are compelling, several caveats merit consideration:

• Species and model limitations: Findings from murine NASH models and in vitro systems may not fully recapitulate human disease complexity or drug pharmacodynamics.
• Pharmacological profile: Although SAR131675 shows preclinical efficacy, its development was discontinued due to adverse metabolic effects in animal studies (product_spec), restricting its immediate translational or therapeutic application.
• Pathway redundancy: The VEGFC–VEGFR-3 axis is one of several parallel pathways involved in fibrosis; compensatory mechanisms may limit efficacy in chronic or advanced disease states.

Nonetheless, the study’s multi-angled approach (pharmacological, genetic, dietary) strengthens the mechanistic link and experimental reproducibility across models.

Why this cross-domain matters, maturity, and limitations

This work bridges vascular biology, immunology, and metabolic disease, revealing how anti-lymphangiogenic compounds can modulate immune–fibrotic crosstalk beyond canonical oncology indications. The maturity of the evidence is robust for preclinical models, but translation to human disease or clinical practice requires further validation and safety optimization (internal article).

Research Support Resources

Researchers aiming to dissect the VEGFC–VEGFR-3 axis in hepatic fibrosis, lymphangiogenesis, or related pathways can utilize SAR131675, a selective and ATP-competitive VEGFR-3 inhibitor (SKU B2301), as a well-characterized tool compound for pathway-specific investigation (product_spec). SAR131675’s selectivity profile also supports its use in distinguishing VEGFR-3-driven effects from other VEGFR family members in advanced fibrotic and angiogenic models. For further insights on mechanistic application and protocol design, researchers may consult the referenced internal reviews above.